Update on the CAPItello-290 Phase III Trial for Truqap Plus Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer
June 19, 2024
June 19, 2024
WILMINGTON, Delaware, June 19 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
The CAPItello-290 Phase III trial for TRUQAP(R) (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer (TNBC) did not meet the dual primary endpoints of improvement in overall survival (OS) versus paclitaxel in combination with placebo in either the overall trial population or in a sub . . .
The CAPItello-290 Phase III trial for TRUQAP(R) (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer (TNBC) did not meet the dual primary endpoints of improvement in overall survival (OS) versus paclitaxel in combination with placebo in either the overall trial population or in a sub . . .